Reshape Lifesciences INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Vyome Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing significant net losses, increased R&D expenses, and a continued reliance on external financing to sustain operations.
Vyome Holdings, Inc. filed its Q1 2026 10-Q, detailing a significant increase in R&D expenses and a new exclusive license agreement for JAK inhibitor assets.
Vyome Holdings, Inc. reported a significant net loss increase in Q3 2025 following its merger with Reshape Lifesciences and a strategic shift towards biotechnology, despite raising substantial capital.
ReShape Lifesciences reported a significant revenue contraction and increased net losses, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.
Reshape Lifesciences reports a net income of $1.474 million for Q1 2025, while navigating a pending merger with Vyome Therapeutics and an asset sale to Ninjour Health International.
ReShape Lifesciences reports a net loss for Q3 2024, while navigating a strategic shift towards a digital model and planning a merger with Vyome Therapeutics.
ReShape Lifesciences reports a decrease in revenue for Q2 2024, alongside a strategic shift towards a digital model and a planned merger with Vyome Therapeutics.
ReShape Lifesciences reported a net loss of $2.193 million for the first quarter of 2024, alongside a decrease in revenue and ongoing concerns about its ability to continue as a going concern.